Company news

Crinetics Pharmaceuticals, Inc. news in 2021

Crinetics Pharmaceuticals, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Crinetics Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

November 17, 2021

Crinetics Pharmaceuticals Presenting New Data from Open Label Extension Trial of Paltusotine in Acromegaly at the Society for Endocrinology BES Congress

November 7, 2021

Crinetics Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 4, 2021

Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

October 24, 2021

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

October 19, 2021

Crinetics Pharmaceuticals to Unveil its Parathyroid Hormone Receptor Antagonist Program at the American Society for Bone and Mineral Research Annual Meeting

September 26, 2021

Crinetics Pharmaceuticals’ Oral SST5 Agonist CRN04777 Demonstrated Pharmacologic Proof-of-Concept with Strong Dose-dependent Suppression of Insulin Secretion in Phase 1 Single Ascending Dose Study

September 14, 2021

Crinetics Pharmaceuticals to Participate in September Investor Conferences

September 6, 2021

Crinetics Pharmaceuticals Expands Executive Team with Addition of Jeff Knight as Chief Operating Officer

September 1, 2021

Crinetics Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

August 9, 2021

Crinetics Pharmaceuticals’ Oral ACTH Antagonist, CRN04894, Demonstrates Pharmacologic Proof-of-Concept with Dose-Dependent Cortisol Suppression in Single Ascending Dose Portion of Phase 1 Study

August 9, 2021

Crinetics Pharmaceuticals Announces $15.0 Million Private Placement with Frazier Healthcare Partners

July 28, 2021

Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly

June 27, 2021

Crinetics Pharmaceuticals Appoints Garlan Adams as General Counsel

June 15, 2021

Crinetics Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

May 5, 2021

Crinetics Pharmaceuticals Announces Closing of Common Stock Offering

April 11, 2021

Crinetics Pharmaceuticals Announces 2021 Clinical Plans and Reports Fourth Quarter and Full Year 2020 Financial Results

March 29, 2021

Crinetics Pharmaceuticals to Host Webcast and Conference Call to Discuss 2021 Clinical Plans and Fourth Quarter and Full Year 2020 Financial Results

March 23, 2021

Crinetics Pharmaceuticals Pipeline Progress on Display at ENDO 2021

March 21, 2021

Crinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on Three Clinical Programs

March 11, 2021

Crinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia and Cushing’s Disease (CRN04894) Advances into Phase 1 Study

February 3, 2021

Crinetics Pharmaceuticals Advances CRN04777 for Congenital Hyperinsulinism into Phase 1 Study

February 2, 2021

Crinetics Pharmaceuticals to Review 2020 Accomplishments and Provide 2021 Plans at 39th Annual J.P. Morgan Healthcare Conference

January 5, 2021

Decks in 2021